NCT06801509尚未招募1 期
A Randomized, Double-blind, Controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Recombinant Herpes Zoster Vaccine in Healthy Adults
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 540
- 试验地点
- 1
- 主要终点
- phase 1: Incidence and intensity of solicited adverse events (AEs)
研究概览
简要总结
The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female subjects ≥ 40 years of age;
- •The subject can and fully understand the trial procedures and voluntarily sign the ICF;
- •The subject is in a healthy state or has stable underlying diseases according to investigator's assessment based on medical history and related physical examination results;
- •The subject can comply with the requirements of the protocol;
- •The axillary temperature of the subject is < 37.0℃ on the day of enrollment;
- •Fertile men and women with childbearing potential voluntarily agree to take effective contraceptive measures from the first vaccination to at least 90 days after the last dose of study vaccines.
排除标准
- •History of herpes zoster before enrollment, or close contact with a varicella/herpes zoster patient within 30 days prior to enrollment;
- •Previous vaccination against herpes zoster and varicella (including vaccines that have been registered or under clinical research);
- •Allergic to any component of the study vaccine, or history of severe allergy to any vaccination, such as anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, local allergic necrosis reaction, angioneurotic edema, etc.
- •History or family history of convulsions, epilepsy, and psychiatric disorders;
- •Suffering from serious chronic diseases or in the active stage of chronic diseases, which are evaluated by the investigator to affect the trial observation, including but not limited to myocardial infarction, severe arrhythmia, unstable angina, hypertension that cannot be controlled after drug treatment (subjects 40-59 years of age have systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, and subjects ≥60 years of age have systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg), diabetes with severe complications, cancer or precancerous lesions, and other serious cerebrovascular diseases, heart disease, respiratory diseases, liver and kidney diseases, and thyroid diseases;
- •Primary or secondary immunosuppressive condition, or diagnosed with primary or acquired immunodeficiency disease, human immunodeficiency virus (HIV) infection, etc.
- •History of thrombocytopenia or other coagulation disorders, which may cause contraindications for intramuscular injection and venous blood collection;
- •Fever (axillary temperature ≥37.3℃) within 3 days before enrollment or systemic antibiotic or antiviral treatment within 7 days;
- •Use of antipyretic analgesics or other drugs with antipyretic and analgesic effects, such as acetaminophen and ibuprofen, within 72 h before vaccination.
- •Abnormal laboratory test (blood routine, blood biochemistry, urine routine) results that are outside the reference range and clinically significant (only apply to Phase I);
- •Those who are pregnant (positive urine pregnancy test) or breast-feeding, or those who plan to become pregnant during the study period;
- •Long-term or high-dose corticosteroid therapy (duration ≥15 days, or dose ≥1 mg/kg/ day of prednisone or equivalent doses of other corticosteroids), or other immunosuppressive and cytotoxic therapy within 90 days prior to vaccination. Short-term or topical use (such as ointments, eye drops, inhalants, intra-articular medications or nasal sprays) of glucocorticoids is permitted;
- •Vaccination with non-attenuated vaccines within 14 days before the first dose of study vaccines, or with live-attenuated vaccines within 28 days before the first dose of study vaccines;
- •Participation in other clinical trials (drug or vaccine) within 30 days preceding the first dose of study vaccines or planning to participate in other clinical trials before this clinical study is completed;
- •Asplenia or functional asplenia;
- •Those who are known to have been diagnosed or currently have an infectious disease, including hepatitis B, hepatitis C, syphilis or AIDS;
- •Those who have any acute illness or acute onset of chronic illness within 72 hours before the first dose of vaccination;
- •Those who have received blood or blood-related products, including immunoglobulins, within 3 months before the first dose of vaccination, or have planned to use them during the study period;
- •Subjects deemed by the investigator to have other conditions that render them ineligible to participate in this study, which include but are not limited to those who are incapable of participating in follow-up visits based on the protocol.
研究组 & 干预措施
Low-Dose Vaccine Group
Experimental
干预措施: Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose (Biological)
High-Dose Vaccine Group
Experimental
干预措施: Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose (Biological)
Shingrix® Group
Active Comparator
干预措施: Shingrix® (Biological)
Ganwei® Group
Active Comparator
Herpes zoster vaccine, live; Changchun BCHT
干预措施: Ganwei® (Biological)
结局指标
主要结局
phase 1: Incidence and intensity of solicited adverse events (AEs)
时间窗: within 14 days after each vaccination
phase 1: Incidence and intensity of unsolicited AEs
时间窗: within 30 days after each vaccination
phase 2: Geometric mean concentration (GMC) and seroconversion rate of antigen-specific antibody
时间窗: at 30 days after full vaccination
次要结局
- phase 2: GMI of antigen-specific antibody(at 30 days after full vaccination)
- phase 2: GMC, GMI, and seroconversion rate of antigen-specific antibody(before the second vaccination, and at 6 months, 12 months and 24 months after full vaccination)
- phase 1: Geometric mean titer (GMT)/ GMC, Geometric mean fold increase (GMI), and seroconversion rate of antigen-, and VZV-specific antibody(at 30 days after the first vaccination, before the second vaccination, and at 30 days after full vaccination)
- phase 1:Frequency and response rate of CD4+ T cells with antigen-specific TNF-α and/or IFN-γ and/or IL-2 and/or CD40L secretion/expression as determined by intracellular cytokine staining (ICS)(at 30 days after the first vaccination, before the second vaccination, and at 30 days after full vaccination)
- phase 2: Frequencies and response rate of CD4+ T cells with antigen-specific TNF-α and/or IFN-γ and/or IL-2 and/or CD40L secretion/expression as determined by ICS(before the second vaccination, and at 30 days, 6 months, 12 months and 24 months after full vaccination)
- phase 1: Incidence of Serious adverse events (SAEs) and Adverse events of special interest (AESIs)(during the study (from the first vaccination to 12 months after full vaccination))
- phase 2: GMT/GMC, GMI, and seroconversion rate of VZV-specific antibody(before the second vaccination, and at 30 days, 6 months, 12 months and 24 months after full vaccination)
- phase 1: Incidence and intensity of abnormal laboratory tests indicators(3 days after each vaccination)
- phase 2: Incidence and intensity of solicited AEs(within 14 days after each vaccination)
- phase 2: Incidence and intensity of unsolicited AEs(within 30 days after each vaccination)
- phase 2: Incidence of SAEs and AESIs(from the first vaccination to 12 months after full vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in AdolescentsMeningococcal DiseaseMeningococcal MeningitisNCT01210885Novartis Vaccines495
已完成
1 期
Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)Streptococcus Pneumoniae InfectionPneumococcal InfectionsNCT02037984Merck Sharp & Dohme LLC341
已完成
2 期
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)Pneumococcal InfectionsNCT02987972Merck Sharp & Dohme LLC1,051
已完成
1 期
Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19SARS-CoV InfectionNCT04751682Bharat Biotech International Limited175
已完成
1 期
First Time in Human Study of ProtexiaIntervention for Nerve Agent ExposureNCT00744146PharmAthene, Inc.33